Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-01-01 Zaleplon, Zolpidem and Zopiclone
| Zolpidem |
|
Formulary
|
| Tablets 5mg, 10mg Stocked for patients admitted on these and for Mental Health patients |
 MHRA: Zolpidem: risk of drowsiness and reduced driving ability |
|
Links
- LSCMMG: Melatonin
- LSCMMG: Melatonin
LSCMMG: Melatonin Pathway (Children) - MHRA Drug Safety Update March 2020: Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression
- MHRA Drug Safety Update Oct 2021:Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication
- MHRA: Changes to drug driving law
- MHRA: Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication
- MHRA: Drugs and driving: blood concentration limits to be set for certain controlled drugs in a new legal offence
- MHRA: Risk of drowsiness and reduced driving ability
- MHRA: Zolpidem: risk of drowsiness and reduced driving ability
- NICE Evidence summary: Melatonin for sleep disorders in children with ADHD
- NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
- NICE TA922: Daridorexant for treating long-term insomnia
- NICE TAG 77 : Zaleplon, zolpidem and zopiclone for the management of insomnia
- NICE TAG 77 :Zaleplon, zolpidem and zopiclone for the management of insomnia